Vera Therapeutics, Inc. (VERA) · INSIDERData sourcesSEC Form 42h ago
House PTR1h ago
SEC 13F1h ago
Robinhood Chain1h ago
Public companyVera Therapeutics, Inc.
VERACIK 0001831828
Price$30.61
1 year+21.4%
Disclosed transactions32
Buys / sells0 / 11
Max Insider Score29
Connections with evidence9
VERA · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 8 | FMFordyce MarshallDirector, PRESIDENT AND CEO | VERAVera Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $685K 18.5K sh | Sep 15, 2026 |
| Sep 17, 2026 traded Sep 15, 2026 |
| 0 | FMFordyce MarshallDirector, PRESIDENT AND CEO | VERAVera Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 18.5K sh | Sep 15, 2026 | Sep 17, 2026 traded Sep 15, 2026 | +2d | SEC Form 4 | |
| 0 | FMFordyce MarshallDirector, PRESIDENT AND CEO | VERAVera Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $54K 18.5K sh | Sep 15, 2026 | Sep 17, 2026 traded Sep 15, 2026 | +2d | SEC Form 4 | |
| 13 | YRYoung Joseph RSVP, FINANCE, CHIEF ACCT OFFCR | VERAVera Therapeutics, Inc. Option exercise | M | — 5,000 sh | Sep 11, 2026 | Sep 14, 2026 traded Sep 11, 2026 | +3d | SEC Form 4 | |
| 13 | YRYoung Joseph RSVP, FINANCE, CHIEF ACCT OFFCR | VERAVera Therapeutics, Inc. Option exercise | M | $20K 5,000 sh | Sep 11, 2026 | Sep 14, 2026 traded Sep 11, 2026 | +3d | SEC Form 4 | |
| 8 | FMFordyce MarshallDirector, PRESIDENT AND CEO | VERAVera Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $650K 18.5K sh | Sep 2, 2026 | Sep 4, 2026 traded Sep 2, 2026 | +2d | SEC Form 4 | |
| 0 | FMFordyce MarshallDirector, PRESIDENT AND CEO | VERAVera Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 18.5K sh | Sep 2, 2026 | Sep 4, 2026 traded Sep 2, 2026 | +2d | SEC Form 4 | |
| 0 | FMFordyce MarshallDirector, PRESIDENT AND CEO | VERAVera Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $54K 18.5K sh | Sep 2, 2026 | Sep 4, 2026 traded Sep 2, 2026 | +2d | SEC Form 4 | |
| 1 | FMFordyce MarshallDirector, PRESIDENT AND CEO | VERAVera Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $3,382 88 sh | Jun 23, 2026 | Jun 24, 2026 traded Jun 23, 2026 | +1d | SEC Form 4 | |
| 11 | FMFordyce MarshallDirector, PRESIDENT AND CEO | VERAVera Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $698K 18.4K sh | Jun 23, 2026 | Jun 24, 2026 traded Jun 23, 2026 | +1d | SEC Form 4 | |
| 15 | | VERAVera Therapeutics, Inc. Grant or award | A | — 17.1K sh | May 21, 2026 | May 26, 2026 traded May 21, 2026 | +5d | SEC Form 4 | |
| 4 | FMFordyce MarshallDirector, PRESIDENT AND CEO | VERAVera Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $159K 4,281 sh | May 12, 2026 | May 13, 2026 traded May 12, 2026 | +1d | SEC Form 4 | |
| 11 | FMFordyce MarshallDirector, PRESIDENT AND CEO | VERAVera Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $521K 14.2K sh | May 12, 2026 | May 13, 2026 traded May 12, 2026 | +1d | SEC Form 4 | |
| 15 | FMFordyce MarshallDirector, PRESIDENT AND CEO | VERAVera Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $617K 14.1K sh | Apr 14, 2026 | Apr 15, 2026 traded Apr 14, 2026 | +1d | SEC Form 4 | |
| 5 | FMFordyce MarshallDirector, PRESIDENT AND CEO | VERAVera Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $41K 900 sh | Apr 14, 2026 | Apr 15, 2026 traded Apr 14, 2026 | +1d | SEC Form 4 | |
| 11 | FMFordyce MarshallDirector, PRESIDENT AND CEO | VERAVera Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $353K 7,921 sh | Apr 14, 2026 | Apr 15, 2026 traded Apr 14, 2026 | +1d | SEC Form 4 | |
| 9 | WJWright-Mitchell JaneChief Legal Officer | VERAVera Therapeutics, Inc. Grant or award | A | — 56.9K sh | Mar 23, 2026 | Mar 25, 2026 traded Mar 23, 2026 | +2d | SEC Form 4 | |
| 9 | WJWright-Mitchell JaneChief Legal Officer | VERAVera Therapeutics, Inc. Grant or award | A | — 42.4K sh | Mar 23, 2026 | Mar 25, 2026 traded Mar 23, 2026 | +2d | SEC Form 4 | |
| 29 | BRBrenner RobertChief Medical Officer | VERAVera Therapeutics, Inc. Open-market sale | SELL | $90K 2,151 sh | Feb 23, 2026 | Feb 25, 2026 traded Feb 23, 2026 | +2d | SEC Form 4 | |
| 29 | SMSkelton Laurence MatthewChief Commercial Officer | VERAVera Therapeutics, Inc. Open-market sale | SELL | $66K 1,582 sh | Feb 23, 2026 | Feb 25, 2026 traded Feb 23, 2026 | +2d | SEC Form 4 | |
| 17 | GSGrant SeanCHIEF FINANCIAL OFFICER | VERAVera Therapeutics, Inc. Grant or award | A | — 25.0K sh | Feb 4, 2026 | Feb 6, 2026 traded Feb 4, 2026 | +2d | SEC Form 4 | |
| 17 | FMFordyce MarshallDirector, PRESIDENT AND CEO | VERAVera Therapeutics, Inc. Grant or award | A | — 68.8K sh | Feb 4, 2026 | Feb 6, 2026 traded Feb 4, 2026 | +2d | SEC Form 4 | |
| 13 | YRYoung Joseph RSVP, FINANCE, CHIEF ACCT OFFCR | VERAVera Therapeutics, Inc. Grant or award | A | — 10.0K sh | Feb 4, 2026 | Feb 6, 2026 traded Feb 4, 2026 | +2d | SEC Form 4 | |
| 9 | FMFordyce MarshallDirector, PRESIDENT AND CEO | VERAVera Therapeutics, Inc. Grant or award | A | — 137.5K sh | Feb 4, 2026 | Feb 6, 2026 traded Feb 4, 2026 | +2d | SEC Form 4 | |
| 21 | TDTurner William D.Chief Regulatory Officer | VERAVera Therapeutics, Inc. Grant or award | A | — 25.0K sh | Feb 4, 2026 | Feb 6, 2026 traded Feb 4, 2026 | +2d | SEC Form 4 | |
| 9 | TDTurner William D.Chief Regulatory Officer | VERAVera Therapeutics, Inc. Grant or award | A | — 50.0K sh | Feb 4, 2026 | Feb 6, 2026 traded Feb 4, 2026 | +2d | SEC Form 4 | |
| 9 | YRYoung Joseph RSVP, FINANCE, CHIEF ACCT OFFCR | VERAVera Therapeutics, Inc. Grant or award | A | — 20.0K sh | Feb 4, 2026 | Feb 6, 2026 traded Feb 4, 2026 | +2d | SEC Form 4 | |
| 9 | GSGrant SeanCHIEF FINANCIAL OFFICER | VERAVera Therapeutics, Inc. Grant or award | A | — 50.0K sh | Feb 4, 2026 | Feb 6, 2026 traded Feb 4, 2026 | +2d | SEC Form 4 | |
| 9 | BRBrenner RobertChief Medical Officer | VERAVera Therapeutics, Inc. Grant or award | A | — 50.0K sh | Feb 4, 2026 | Feb 6, 2026 traded Feb 4, 2026 | +2d | SEC Form 4 | |
| 17 | SMSkelton Laurence MatthewChief Commercial Officer | VERAVera Therapeutics, Inc. Grant or award | A | — 20.0K sh | Feb 4, 2026 | Feb 6, 2026 traded Feb 4, 2026 | +2d | SEC Form 4 | |
| 21 | BRBrenner RobertChief Medical Officer | VERAVera Therapeutics, Inc. Grant or award | A | — 25.0K sh | Feb 4, 2026 | Feb 6, 2026 traded Feb 4, 2026 | +2d | SEC Form 4 | |
| 9 | SMSkelton Laurence MatthewChief Commercial Officer | VERAVera Therapeutics, Inc. Grant or award | A | — 40.0K sh | Feb 4, 2026 | Feb 6, 2026 traded Feb 4, 2026 | +2d | SEC Form 4 | |
Chief Medical Officer · Feb 6, 2026